No CrossRef data available.
Article contents
If Long-Term Suppression is not Possible, how do we Minimize Mortality for Infectious Disease Outbreaks?
Published online by Cambridge University Press: 01 December 2023
Abstract
Objective:
For any emerging pathogen, the preferred approach is to drive it to extinction with non-pharmaceutical interventions (NPI) or suppress its spread until effective drugs or vaccines are available. However, this might not always be possible. If containment is infeasible, the best people can hope for is pathogen transmission until population level immunity is achieved, with as little morbidity and mortality as possible.
Methods:
A simple computational model was used to explore how people should choose NPI in a non-containment scenario to minimize mortality if mortality risk differs by age.
Results:
Results show that strong NPI might be worse overall if they cannot be sustained compared to weaker NPI of the same duration. It was also shown that targeting NPI at different age groups can lead to similar reductions in the total number of infected, but can have strong differences regarding the reduction in mortality.
Conclusions:
Strong NPI that can be sustained until drugs or vaccines become available are always preferred for preventing infection and mortality. However, if people encounter a worst-case scenario where interventions cannot be sustained, allowing some infections to occur in lower-risk groups might lead to an overall greater reduction in mortality than trying to protect everyone equally.
Keywords
- Type
- Original Research
- Information
- Copyright
- © The Author(s), 2023. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc
References
Stern, AM, Markel, H. International efforts to control infectious diseases, 1851 to the present. JAMA. 2004;292(12):1474-9.CrossRefGoogle ScholarPubMed
Lipsitch, M, Riley, S, Cauchemez, S, et al. Managing and reducing uncertainty in an emerging influenza pandemic. N Engl J Med. 2009;361(2):112-5.CrossRefGoogle Scholar
Heymann, DL. The international response to the outbreak of SARS in 2003. Philos Trans R Soc Lond B Biol Sci. 2004;359(1447):1127–9.CrossRefGoogle Scholar
Coltart, CEM, Lindsey, B, Ghinai, I, et al. The Ebola outbreak, 2013-2016: old lessons for new epidemics. Philos Trans R Soc Lond B Biol Sci. 2017;372(1721):20160297.CrossRefGoogle ScholarPubMed
Jhung, MA, Swerdlow, D, Olsen, SJ, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis. 2011;52 Suppl 1:S13-26.CrossRefGoogle Scholar
Dawood, FS, Iuliano, AD, Reed, C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-95.CrossRefGoogle ScholarPubMed
Buss, LF, Prete, CA, Abrahim, CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science. 2021;371(6526):288-92.CrossRefGoogle ScholarPubMed
Bilinski, A, Emanuel, EJ. COVID-19 and excess all-cause mortality in the US and 18 comparison countries. JAMA. 2020;324(20):2100–2.CrossRefGoogle ScholarPubMed
Kissler, SM, Tedijanto, C, Goldstein, E, et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860-8.CrossRefGoogle ScholarPubMed
Lavine, JS, Bjornstad, ON, Antia, R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science. 2021;371(6530):741-5.CrossRefGoogle ScholarPubMed
Bubar, KM, Reinholt, K, Kissler, SM, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371(6532):916-21.CrossRefGoogle ScholarPubMed
Hatchett, RJ, Mecher, CE, Lipsitch, M. Public health interventions and epidemic intensity during the 1918 influenza pandemic. Proc Natl Acad Sci USA. 2007;104(18):7582-7.CrossRefGoogle ScholarPubMed
Du, Z, Wang, Y, Bai, Y, et al. Estimate of COVID-19 deaths, China, December 2022 - February 2023. Emerg Infect Dis. 2023;29(10):2121–4.CrossRefGoogle Scholar
Liu, W, Fontanet, A, Zhang, PH, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792-5.CrossRefGoogle ScholarPubMed
Payne, DC, Iblan, I, Rha, B, et al. Persistence of antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg Infect Dis. 2016;22(10):1824-6.CrossRefGoogle ScholarPubMed
Wu, LP, Wang, NC, Chang, YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562-4.CrossRefGoogle ScholarPubMed
McElroy, AK, Akondy, RS, Davis, CW, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA. 2015;112(15):4719-24.CrossRefGoogle ScholarPubMed
Rydyznski, MC, Ramirez, SI, Dan, JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and Associations with age and disease severity. Cell. 2020;183(4):996-1012.e19.CrossRefGoogle Scholar
Handel, A, Longini, IM, Antia, R. What is the best control strategy for multiple infectious disease outbreaks? Proc Biol Sci. 2007;274(1611):833-7.Google ScholarPubMed
Fung, ICH, Antia, R, Handel, A. How to minimize the attack rate during multiple influenza outbreaks in a heterogeneous population. PloS One. 2012;7(6):e36573.CrossRefGoogle Scholar
Lauro, FD, Kiss, IZ, Miller, JC. Optimal timing of one-shot interventions for epidemic control. PloS Comput Biol. 2021;17(3):e1008763.CrossRefGoogle ScholarPubMed
Mizumoto, K, Chowell, G. Estimating risk for death from 2019 novel coronavirus disease, China, January–February 2020. Emerg Infect Dis 2020; 26(6):1251-1256.CrossRefGoogle ScholarPubMed
Verity, R, Okell, LC, Dorigatti, I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–77.CrossRefGoogle ScholarPubMed
Mossong, J, Hens, N, Jit, M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PloS Med. 2008;5(3):e74.CrossRefGoogle Scholar
Klepac, P, Kucharski, AJ, Conlan, AJ, et al. Contacts in context: large-scale setting-specific social mixing matrices from the BBC Pandemic project [Internet]. Cold Spring Harbor Laboratory Press; 2020. https://www.medrxiv.org/content/early/2020/03/05/2020.02.16.20023754
Google Scholar
Steele, MK, Remais, JV, Gambhir, M, et al. Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options. Epidemics. 2016;17:42-9.CrossRefGoogle ScholarPubMed
Li, Q, Guan, X, Wu, P, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-207.CrossRefGoogle ScholarPubMed
Billah, MA, Miah, MM, Khan, MN. Reproductive number of coronavirus: a systematic review and meta-analysis based on global level evidence. PloS One. 2020;15(11):e0242128.CrossRefGoogle ScholarPubMed
Wölfel, R, Corman, VM, Guggemos, W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–9.CrossRefGoogle ScholarPubMed
Monod, M, Blenkinsop, A, Xi, X, et al. Age groups that sustain resurging COVID-19 epidemics in the United States. Science. 2021;371(6536):eabe8372.CrossRefGoogle ScholarPubMed
Sridhar, D, Gurdasani, D. Herd immunity by infection is not an option. Science. 2021;371(6526):230-1.CrossRefGoogle Scholar
Great Barrington Declaration [Internet]. Great Barrington declaration and petition. https://gbdeclaration.org/. Accessed October 7, 2023.Google Scholar
Fontanet, A, Cauchemez, S. COVID-19 herd immunity: where are we? Nat Rev Immunol. 2020;20(10):583–4.CrossRefGoogle ScholarPubMed
Omer, SB, Yildirim, I, Forman, HP. Herd immunity and implications for SARS-CoV-2 control. JAMA. 2020;324(20):2095-6.CrossRefGoogle ScholarPubMed
Dyer, O. Covid-19: black people and other minorities are hardest hit in US. BMJ. 2020;369:m1483.CrossRefGoogle ScholarPubMed
Soltesz, K, Gustafsson, F, Timpka, T, et al. The effect of interventions on COVID-19. Nature. 2020;588(7839):E26-8.CrossRefGoogle ScholarPubMed
Liu, Y, Morgenstern, C, Kelly, J, et al. The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC Med. 2021;19(1):40.CrossRefGoogle ScholarPubMed
Stutt, ROJH, Retkute, R, Bradley, M, et al. A modelling framework to assess the likely effectiveness of facemasks in combination with 'lock-down' in managing the COVID-19 pandemic. Proc Math Phys Eng Sci. 2020;476(2238):20200376.Google ScholarPubMed
Kucharski, AJ, Russell, TW, Diamond, C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis. 2020;20(5):553-8.CrossRefGoogle ScholarPubMed
Jackson, C, Vynnycky, E, Hawker, J, et al. School closures and influenza: systematic review of epidemiological studies. BMJ Open. 2013;3(2):e002149.CrossRefGoogle ScholarPubMed
Fung, ICH, Gambhir, M, Glasser, JW, et al. Modeling the effect of school closures in a pandemic scenario: exploring two different contact matrices. Clin Infect Dis. 2015;60 Suppl 1:S58-63.CrossRefGoogle Scholar
Navarro, JA, Kohl, KS, Cetron, MS, et al. A tale of many cities: a contemporary historical study of the implementation of school closures during the 2009 pA(H1N1) Influenza pandemic. J Health Polit Policy Law. 2016;41(3):393-421.CrossRefGoogle ScholarPubMed
Garza, RC, Basurto-Dávila, R, Ortega-Sanchez, IR, et al. Effect of winter school breaks on influenza-like illness, Argentina, 2005-2008. Emerg Infect Dis. 2013;19(6):938-44.CrossRefGoogle ScholarPubMed
Miller, JC, Danon, L, O’Hagan, JJ, et al. Student behavior during a school closure caused by pandemic influenza A/H1N1. PloS One. 2010;5(5):e10425.CrossRefGoogle ScholarPubMed
Handel et al. supplementary material 1
File
170.5 KB
Handel et al. supplementary material 2
File
1.9 KB
Handel et al. supplementary material 3
File
2.7 KB
Handel et al. supplementary material 4
File
2.5 KB